Oregon Public Employees Retirement Fund trimmed its position in shares of Catalent Inc (NYSE:CTLT) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 55,731 shares of the company’s stock after selling 3,948 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Catalent were worth $3,138,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Huntington National Bank purchased a new stake in shares of Catalent in the fourth quarter valued at $32,000. Squar Milner Financial Services LLC lifted its position in shares of Catalent by 173.4% in the fourth quarter. Squar Milner Financial Services LLC now owns 659 shares of the company’s stock valued at $37,000 after acquiring an additional 418 shares in the last quarter. Evoke Wealth LLC purchased a new stake in shares of Catalent in the third quarter valued at $42,000. Quest Capital Management Inc. ADV purchased a new stake in shares of Catalent in the third quarter valued at $53,000. Finally, Exchange Traded Concepts LLC purchased a new stake in shares of Catalent in the fourth quarter valued at $90,000.
Several research firms recently weighed in on CTLT. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a research report on Monday, February 3rd. Morgan Stanley increased their target price on Catalent from $64.00 to $67.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Stephens increased their target price on Catalent from $65.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $67.00 target price (up from $60.00) on shares of Catalent in a research report on Tuesday, February 4th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Catalent presently has a consensus rating of “Buy” and an average price target of $62.43.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, February 3rd. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.06. The company had revenue of $721.40 million during the quarter, compared to analyst estimates of $700.81 million. Catalent had a return on equity of 15.21% and a net margin of 5.44%. The firm’s revenue was up 15.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.45 earnings per share. Equities analysts predict that Catalent Inc will post 1.78 EPS for the current year.
In other Catalent news, COO Alessandro Maselli sold 7,268 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $53.18, for a total transaction of $386,512.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Aristippos Gennadios sold 45,256 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $52.55, for a total value of $2,378,202.80. The disclosure for this sale can be found here. Insiders have sold 55,512 shares of company stock valued at $2,921,998 over the last 90 days. 1.30% of the stock is currently owned by insiders.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: How to identify percentage decliners
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.